Samsung Bioepis has teamed with C-Bridge Capital to bring its third-wave biosimilars to the Chinese market.
C-Bridge will establish a new company, AffaMed Therapeutics, under terms of the deal, and will license multiple biosimilar candidates from Samsung Bioepis to commercialize in China. These include the third-wave biosimilar candidates SB11 and SB12 – versions of Roche/Novartis’ Lucentis (ranibizumab) and Alexion’s Soliris (eculizumab) – and SB3, a biosimilar of Roche’s Herceptin (trastuzumab).
The deal comes weeks after a partnership deal with 3SBio Inc to help bring other Samsung Bioepis biosimilar candidates into China, including a version of Roche’s Avastin (bevacizumab).
Samsung Bioepis has teamed with C-Bridge Capital and 3SBio in separate deals to commercialize biosimilars in China